Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

作者：Sung‐Bae Kim, Rebecca Dent, Seock‐Ah Im, Marc Espié, Sibel Blau, Antoinette R. Tan, Steven J. Isakoff, Mafalda Oliveira, Cristina Saura, Matthew Wongchenko, Amy V. Kapp, Wai Yee Chan, Stina Mui Singel, Daniel Maslyar, José Baselga, Sungbae Kim, Keun Seok Lee, Seock‐Ah Im, Marc Espié, Hwei-Chung Wang, Sibel Blau, Rebecca Dent, Antoinette R. Tan, Joohyuk Sohn, Michelino De Laurentiis, Laura García‐Estévez, Chiun‐Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva-Vázquez, PierFranco Conte, Shaker R. Dakhil, Marc Debled, Antonio González-Martı́n, Sara A. Hurvitz, Jee Hyun Kim, Christelle Lévy, Mafalda Oliveira, Pedro Sánchez‐Rovira, Jae Hong Seo, Vicente Valero, Gregory A. Vidal, Andrea Wong, Mary Ann Allison, Robert A. Figlin, David Chan, Shin‐Cheh Chen, Yen‐Hsun Chen, Melody Cobleigh, Filippo de Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven J. Isakoff, William Lawler, Álvaro Montaño, Mohamad Salkini, L. Seigel · 发表于：The Lancet Oncology · 年份：2017 · DOI：10.1016/s1470-2045(17)30450-3 · 被引用次数：478 · 研究领域：PI3K/AKT/mTOR signaling in cancer、Advanced Breast Cancer Therapies、Cancer, Lipids, and Metabolism